Sign in
RNA Stock Price, Chart, Stats & News
Atrium Therapeutics, Inc.
Save
211.60M
Market cap
–
Current P/E
–
Forward P/E
RNA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -412.58% |
Pretax margin | -412.64% |
Net margin | -411.88% |
Effective tax rate | 0.18% |
ROA | -27.55% |
ROE | -36.99% |
D/E | 0.02x |
Interest coverage ratio | – |
RNA valuation
P/E | – |
P/S | 11.02x |
P/B | 1.09x |
P/CF | -5.51x |
P/FCF | -4.82x |
P/OCF | -5.51x |
PEG | -0.03x |
EV multiple | -6.17x |
About
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases.
Similar securities
Based on sector and market capitalization
Report issue